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Background: An important limiting factor for clinical research is the high cost of trials, mainly due to the large sample size required. In this study, 
we evaluated the use of coronary artery calcium score (CACS) to identify at-risk population for primary prevention trials.
Methods: 6416 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) were stratified according to the inclusion criteria for three 
primary prevention statin trials (MEGA, AFCAPS/TexCAPS and ALLHAT). We compared coronary heart disease (CHD) event rates, Cox adjusted hazard 
ratios, the 5-year number needed to treat (NNT) stratified by CACS. NNT was calculated using the observed absolute risk reduction observed in each 
study. Additionally, assuming an alpha error of 0.05, a power of 0.90 and a 5-year follow up, we calculated the expected sample size required using 
different CACS thresholds as entry criteria.
results: The results for the event rates over a 7.6 year follow up, hazard ratios, 5-year NNTs are presented in the figure. For the primary outcome of 
CHD events, the estimated sample size based on MESA event rates would be 10,796; 4610; and 103,550 patients for the MEGA, AFCAPS/TexCAPS 
and ALLHAT trials, respectively. Using CAC>0 as a threshold would reduce the sample size by approximately 50%, whereas the use of CAC>100 would 
result in an additional sample size reduction. (Figure)
conclusion: The use of CAC as inclusion criteria may allow for substantial reductions in sample size, and thus cost, of primary prevention trials. 
